skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Predictors of premature discontinuation of treatment in multiple disease states

Original Research

(2565) Views  (566) Full article downloads

Authors: Eric Nantz, Hong Liu-Seifert, Vladimir Skljarevski

Published Date January 2009 Volume 2009:3 Pages 31 - 43
DOI: http://dx.doi.org/10.2147/PPA.S4633

Eric Nantz1, Hong Liu-Seifert2, Vladimir Skljarevski2

1Department of Statistics, Western Michigan University, Kalamazoo, MI, USA; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

Background: Premature discontinuation of treatment impacts outcomes of clinical practice. The traditional perception has been patient discontinuation is mainly driven by unwanted side effects. Systematic analysis of data from clinical trials across several disease states was performed to identify predictors of premature discontinuation during clinical interventions.

Methods: A post hoc analysis was conducted on 22 randomized, double-blind, placebo-controlled clinical trials for treatment of fibromyalgia, diabetic peripheral neuropathic pain, major depressive disorder, and generalized anxiety disorder. Analyses were conducted on pooled data within each disease state.

Results: Lack of early therapeutic response was a significant predictor of patient discontinuation in each disease state. Visit-wise changes in therapeutic response and severity of adverse events were also significant risk factors, with change in therapeutic response having a higher significance level in three disease states. Patients who discontinued due to adverse events had similar therapeutic responses as patients completing treatment.

Conclusion: Contrary to the conventional belief that premature treatment discontinuation is primarily related to adverse events, our findings suggest lack of therapeutic response also plays a significant role in patient attrition. This research highlights the importance of systematic monitoring of therapeutic response in clinical practice as a measure to prevent patients’ discontinuation from pharmacological treatments.

Keywords: attrition, depression, generalized anxiety disorder, fibromyalgia, therapeutic response, adverse event








Readers of this article also read:

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
Ten lessons learned from conducting an adherence intervention trial
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism
Concordance, compliance, preference or adherence
Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy